Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: Psychopharmacology (Berl). 2011 Dec 13;221(3):479–492. doi: 10.1007/s00213-011-2595-7

Fig 9.

Fig 9

Topographic distribution of (A, B) KCl –evoked DA release and (C, D) clearance in the striatum in loxP-PPARγ/AAV-Cre (red tracing) and WT/AAV-Cre (black tracing) at 2 months after high dose MA administration. (A) The release of dopamine elicited by KCl in the L striatum of mice was significantly reduced, compared to the L striatum in WT/AAV-Cre mice (p<0.05, two way ANOVA + Newman-Keuls test). Most of these differences were in dorsal striatum. (B) No difference was found in the R striatum between WT/AAV-Cre and loxP-PPARγ/AAV-Cre mice. (C) A reduction in DA clearance was seen in the L striatum in loxP-PPARγ/AAV-Cre mice (p<0.05, two way ANOVA). (D) No difference in clearance was found in the contralateral striatum between WT/AAV-Cre and loxP-PPARγ/AAV-Cre mice.